Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 13/20 | 0.57 |
| ▸ | BUB1 | O43683 | 5/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etriciguat SCHEMBL419874 | 0.89 | ADORA3 (0.56) | PDE5ABUB1ADORA3KCNH2 | |
| Etriciguat SCHEMBL29388720 | 0.89 | ADORA3 (0.56) | PDE5ABUB1ADORA3KCNH2 | |
| SCHEMBL6859150 | 0.86 | PDE5A (0.62) | PDE5AADORA3KCNH2 | |
| SCHEMBL18212218 | 0.83 | ADORA3 (0.58) | PDE5AADORA3KCNH2 | |
| SCHEMBL6068522 | 0.81 | ADORA3 (0.49) | PDE5ABUB1ADORA3KCNH2 | |
| SCHEMBL15087495 | 0.81 | PDE5A (0.57) | PDE5AADORA3KCNH2 | |
| SCHEMBL174574 | 0.81 | PDE5A (0.62) | PDE5ABUB1ADORA3KCNH2 | |
| SCHEMBL175137 | 0.80 | PDE5A (0.61) | PDE5ABUB1ADORA3KCNH2 | |
| SCHEMBL6156803 | 0.80 | ADORA3 (0.54) | PDE5ABUB1ADORA3KCNH2 | |
| SCHEMBL6156593 | 0.80 | PDE5A (0.53) | PDE5ABUB1ADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885BUB1 4809/4885ADORA3 1070/4885 |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | NR3C2, GUCY1A1, GUCY1A2 | PDE5A 22/4885BUB1 4710/4885ADORA3 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.